TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Up 0.6% – What’s Next?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s share price shot up 0.6% during mid-day trading on Thursday . The company traded as high as $8.82 and last traded at $8.74. 1,541 shares were traded during mid-day trading, a decline of 83% from the average session volume of 8,939 shares. The stock had previously closed at $8.69.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $280.00.

TransCode Therapeutics Price Performance

The business has a 50-day simple moving average of $9.57 and a 200 day simple moving average of $9.80. The firm has a market cap of $8.04 million, a PE ratio of -0.32 and a beta of 1.49.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.